Statin‐associated muscle symptoms (SAMS) can lead to statin nonadherence. This paper aims to develop a pharmacological SAMS risk stratification (PSAMS‐RS) score using a previously developed PSAMS phenotyping algorithm that distinguishes objective vs. nocebo SAMS using electronic health record (EHR) data. Using our PSAMS phenotyping algorithm, SAMS cases and controls were identified from Minnesota Fairview EHR, with the statin user cohort divided into derivation (January 1, 2010, to December 31, 2018) and validation (January 1, 2019, to December 31, 2020) cohorts. A Least Absolute Shrinkage and Selection Operator regression model was applied to identify significant features for PSAMS. PSAMS‐RS scores were calculated and the clinical utility of stratifying PSAMS risk was assessed by comparing hazard ratios (HRs) between fourth vs. first score quartiles. PSAMS cases were identified in 1.9% (310/16,128) of the derivation and 1.5% (64/4,182) of the validation cohorts. Sixteen out of 38 clinical features were determined to be significant predictors for PSAMS risk. Patients within the fourth quartile of the PSAMS scores had an over sevenfold (HR: 7.1, 95% confidence interval (CI): 4.03–12.45, derivation cohort) or sixfold (HR: 6.1, 95% CI: 2.15–17.45, validation cohort) higher hazard of developing PSAMS vs. those in their respective first quartile. The PSAMS‐RS score is a simple tool to stratify patients' risk of developing PSAMS after statin initiation which could inform clinician‐guided pre‐emptive measures to prevent PSAMS‐related statin nonadherence.
1 December 2023 in Experimental Biology and Medicine
In our previous study, we demonstrated the feasibility of producing a proactive statin prescription strategy – a personalized statin treatment plan (PSTP) – using neural networks with big data. However, its non-transparency limited result interpretations and clinical usability. To improve the transparency of our previous approach with minimal compromise to the maximal statin treatment benefit-to-risk ratio, this study proposed a five-step pipeline approach called the decision rules for statin treatment (DRST). Steps 1–3 of our proposed pipeline improved our previous PSTP model in optimizing individual benefit-to-risk ratio; Step 4 used a decision tree model (DRST) to provide straightforward rules in the initial statin treatment plan; Step 5 aimed to evaluate the efficacy of these decision rules by conducting a clinical trial simulation. We included 107,739 de-identified patient data from Optum Labs Database Warehouse in this study. The final decision rules were compact and efficient, resulting from a decision tree with only a maximum depth of 3 and 11 nodes. The DRST identified three factors that are easily obtainable at the point of care: age, low-density lipoprotein cholesterol (LDL-C) level, and age-adjusted Charlson score. Moreover, it also identified six subpopulations that can benefit most from these decision rules. In our clinical trial simulations, DRST was found to improve statin benefit in LDL-C reduction by 4.15 percentage points (pp) and reduce risks of statin-associated symptoms (SAS) and statin discontinuation by 11.71 and 3.96 pp, respectively, when compared to the standard of care. Moreover, these DRST results were only less than 0.6 pp suboptimal to PSTP, demonstrating that building DRST that provide transparency with minimal compromise to the maximal benefit-to-risk ratio of statin treatments is feasible.
Introduction: Clinical decision support (CDS) that does not optimize individual variability with best practice and treatment outcomes, cannot support patient-centered care. For example, a statin treatment CDS focused on cholesterol reduction without accounting for patient comorbidities, at risk lifestyle, or genetics, may well suggest a treatment that increases adverse effects, has a high cost, and has a low potential for improved outcome. We present a novel patient-centered decision support (PCDS) system for statin initiation that accounts for best practice and patient variation and ranks treatment options by their predicted ability to improve cardiac outcomes and reduce adverse effects for individual patients. Method: A total of 30 M de-identified claim records from 1.4 M adults receiving statin treatment over 1990-2020 are available in the OptumLabs® Data Warehouse and were used to train our counterfactual prediction algorithm. For a new patient, the PCDS system predicts LDL reduction, cardiac events, and other outcomes at 1 and 5 years, for every potential statin treatment. The PCDS then integrates doctor and patient preferences into a multi-objective optimization algorithm to generate a ranked list of treatment options. Conclusion: Our novel patient-centered decision support (PCDS) adds sophisticated AI modeling and optimization to account for evidenced-based best practice, patient variability, and adverse effect risk to produce a clear ranking of treatment options that can be re-ranked upon input of patient preferences and provider’s lifestyle, socioeconomics, culture, experience and environment factors. This PCDS approach leverages traditional CDS adjusted to individual preferences to aligned with the patient-centered care model.
Background: Patients with dementia frequently present with multiple chronic conditions (MCCs). Growing evidence indicates these conditions do not co-occur by chance but may interact in ways that accelerate cognitive decline. In this study, we presented a machine-learning framework to identify these non-random, personalized MCC patterns associated with dementia, based on patients’ pre-existing conditions. Furthermore, we demonstrated a patient example illustrating how this approach enables the early detection of emerging MCC trajectories. Methods: To address this challenge, we introduced a lazy decision tree (lazyDT-MCCPath) framework using National Alzheimer’s Coordinating Center data. For each patient, lazyDT-MCCPath dynamically fine-tunes its training distribution based on pre-existing conditions from the preceding 3-5 years, while remaining MCCs were used to predict dementia risk. The decision tree provides a transparent pathway showing which emerging MCCs were associated with higher dementia risk. Results: Unlike traditional eager decision trees (eagerDT), which lacked sufficient training data for 17%-33% of patient profiles, lazyDT-MCCPath successfully modeled all profiles and achieved a 0.17 improvement in AUROC (0.66 vs. 0.83). Conclusions: lazyDT-MCCPath effectively translates pre-existing MCC profiles into personalized dementia risk probabilities for emerging conditions, which may help clinicians prioritize MCCs to monitor more closely.